Limited sampling strategy for mycophenolic acid area under the curve

Therapeutic Drug Monitoring

Volumn 22, Issue 2, 2000, Pages 169-173

  Filler, Guido ^a,b   Mai, Ingrid ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

Area under the curve; Mycophenolate mofetil; Mycophenolic acid; Pharmacokinetics

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; DOSE TIME EFFECT RELATION; DRUG MONITORING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; PREDICTION; PRIORITY JOURNAL; SAMPLING; SCHOOL CHILD;

ADOLESCENT; ADULT; AREA UNDER CURVE; CHILD; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID;

EID: 0034042130     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200004000-00005     Document Type: Article

References (20)

1. van der Woude FJ. Mycophenolate mofetil (RS 61443): nothing new under the sun or an important break-through in the field of transplantation? Nephrol Dial Transplant 1995;10:1112-15
2. Allison AC, Eugui EM. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev 1993;136:5-28
3. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995;345:1321-25
4. Ettenger R, Menster B, Warshaw B, Potter D, Nichols A. Mycophenolate mofetil (MMF) in pediatric (ped) renal transplantation (TX): Final report of the pediatric MMF study group (PMMFSG). 30th Annual Meeting of the American Society of Nephrology, November 2-5, 1997; San Antonio, TX. A3174.
5. Weber LT, Shipkova M, Lamersdorf T, et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. J Am Soc Nephrol 1998;9(8):1511-1520
6. Jacqz-Agrain E, Khan Shaghaghi E, Baudouin V, et al. Pharmacokinetics and tolerance of mycophenoalte mofetil in pediatric renal transplant recipients. Pediatr Nephrol, in press.
7. Filler G, Lampe D, Mai I, Strehlau J, Ehrich JHH. Reduced dosing of MMF in combination with tacrolimus for steroid resistant, vascular rejection in renal allografts. Transpl Int 1998;11(Suppl1):82-85
8. Zucker K, Rosen A, Tsaroucha A, et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl Immunol 1997; 5(3):225-232
9. Filler G, Ehrich JHH. Mycophenolic mofetil for rescue therapy in acute renal transplant rejection in children should always be monitored by measurement of trough concentration. Nephrol Dial Transplant 1997;12:374-5
10. Shaw LM, Kaplan B, Kaufman D. Toxic effects of immunosuppressive drugs: Mechanisms and strategies for controlling them. Clin Chem 1996;42:1316-21
11. Hale MD, Nicholls AJ, Bullingham RE, et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998;64(6):672-83
12. Bauer S, Mai I, Roots I. Modification of the Abbott IMx Tacrolimus (FK-506) assay for estimation of low FK-506 blood levels. Naunyn Schmiedebergs Arch Pharmacol 1996;353:(R149)
13. Schütz E, Shipkova M, Armstrong VW, et al. Therapeutic drug monitoring of mycophenolic acid: comparison of HPLC and immunoassay reveals new MPA metabolites. Transplant Proc 1998; 30(4):1185-1187
14. Bland M, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1: 307-310
15. Schütz E, Armstrong VW, Shipkova M, et al. Limeted sampling strategy for the determination of mycophenolic acid area under the curve in pediatric kindey recipients. German Study Group on MMF Therapy in Pediatric Renal Transplant Recipients. Transplant Proc 1998;30(4):1182-4
16. Filler G, Zimmering M, Mai I. Pharmacokinetics of Mycophenolate mofetil are Influenced by Concomitant Immunosuppression. Pediatr Nephrol (in press)
17. Kaplan B, Meier-Kriesche HU, Friedman G, et al. The effect of renal insufficiency on mycophenolic acid protein binding. J Clin Pharmacol 1999;39(7):715-20
18. Langman LJ, LeGatt DF, Halloran PF, Yatscoff RW. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients. Transplantation 1996;62(5): 666-672
19. Bullingham R, Monroe S, Nicholls A, Hale M. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 1996;36(4):315-324
20. Filler G, Mai I, Filler S, Enrich JH. Abbreviated cyclosporine AUCs on Neoral - the search continues! Pediatr Nephrol 1999;13: 98-102